Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019838 · ClinicalTrials.gov registry record · Phase 1
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00019838: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019838 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019838, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when given with UCN-01 in treating patients with recurrent or refractory low-grade lymphoma or leukemia.
Interventions
- DRUG fludarabine phosphate
- DRUG 7-hydroxystaurosporine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Phase | Phase 1 |
What the finished NCT00019838 record still lists
NCT00019838 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which fludarabine phosphate is the first listed.
NCT00019838 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019838 about?
NCT00019838 is a clinical study titled "UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia". RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when given with UCN-01 in ...
What is the current status of trial NCT00019838?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07.
What interventions are being tested in trial NCT00019838?
The interventions under investigation include: fludarabine phosphate (DRUG), 7-hydroxystaurosporine (DRUG).
Who is sponsoring clinical trial NCT00019838?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia